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We evaluated the effect of acute and chronic GVHD on
relapse and survival after allogeneic hematopoietic SCT
(HSCT) for multiple myeloma using non-myeloablative
conditioning (NMA) and reduced-intensity conditioning
(RIC). The outcomes of 177 HLA-identical sibling HSCT
recipients between 1997 and 2005, following NMA
(n¼ 98) or RIC (n¼ 79) were analyzed. In 105 patients,
autografting was followed by planned NMA/RIC allo-
geneic transplantation. The impact of GVHD was
assessed as a time-dependent covariate using Cox models.
The incidence of acute GVHD (aGVHD; grades I–IV)
was 42% (95% conﬁdence interval (CI), 35–49%) and of
chronic GVHD (cGVHD) at 5 years was 59% (95%
CI, 49–69%), with 70% developing extensive cGVHD.
In multivariate analysis, aGVHD (Xgrade I) was
associated with an increased risk of TRM (relative risk
(RR)¼ 2.42, P¼ 0.016), whereas limited cGVHD
signiﬁcantly decreased the risk of myeloma relapse
(RR¼ 0.35, P¼ 0.035) and was associated with superior
EFS (RR¼ 0.40, P¼ 0.027). aGVHD had a detrimental
effect on survival, especially in those receiving autologous
followed by allogeneic HSCT (RR¼ 3.52, P¼ 0.001).
The reduction in relapse risk associated with cGVHD is
consistent with a beneﬁcial graft-vs-myeloma effect, but
this did not translate into a survival advantage.
Bone Marrow Transplantation (2012) 47, 831–837;
doi:10.1038/bmt.2011.192; published online 26 September 2011
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Introduction
Some studies suggest a graft-vs-myeloma effect after
allogeneic hematopoietic SCT (HSCT) for multiple myelo-
ma (MM).1–4 For example, donor lymphocyte infusions
have induced remission in patients with recurrent MM after
HSCT. In recipients of allogeneic HSCT after traditional
myeloablative conditioning, the graft-vs-myeloma effect is
suggested by the fact that chronic GVHD (cGVHD)
correlates with CR.5 However, other studies report no
correlation.6 Despite the beneﬁcial graft-vs-myeloma effect,
the high treatment-related mortality, mainly related to
GVHD, has made myeloablative HSCT unattractive
compared with autologous transplants or new drugs.7–9
Recently, allogeneic transplantations have been used earlier
in the course of MM and with reduced conditioning intensity,
in an attempt to reduce TRM after HSCT.10 A promising
approach is the combination of high-dose chemotherapy
and autologous transplant, followed by reduced-intensity
HSCT.11 This approach relies on a maximal disease control
strategy with autologous transplantation, followed by lower-
intensity conditioning allogeneic HSCT to achieve an
immune-mediated graft-vs-myeloma effect.6,11–14 Two rando-
mized studies in high-risk MM patients indicated that
autologous followed by allogeneic HSCT had similar out-
comes compared with tandem autologous transplant-
ation.13,14 Studies not limited to high-risk MM patients with
autologous followed by allogeneic approach, compared with
tandem autologous transplantation, have shown discordant
results with an earlier Italian study showing a survival
advantage, whereas the recently reported Bone Marrow
Transplant Clinical Trials Network 0102 Study showed no
beneﬁt to allogeneic transplantation.12,15
With reduction in conditioning intensity, any beneﬁcial
effect of allogeneic HSCT is likely to be derived from
an immune-mediated graft-vs-MM effect, but the relative
impact of this effect has been difﬁcult to characterize.
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A retrospective study by Crawley et al.16 showed that
cGVHD was associated with superior survival in patients
treated with reduced-intensity allogeneic transplantation.
Another prospective study suggested no correlation
between cGVHD and response in patients undergoing
autologous followed by allogeneic HSCT for MM.6
Interestingly, the study by Crawley et al.16 did not
speciﬁcally address the upfront planned autologous
followed by allogeneic HSCT approach.
We analyzed the impact of acute and chronic GVHD on
outcomes in myeloma patients undergoing allogeneic
HSCT, following reduced-intensity conditioning (RIC),
both in the planned autologous followed by allogeneic
(auto-allo) and the single upfront allogeneic HSCT (not
preceded by autotransplant) settings.
Patients and methods
Patient selection
Recipients of HLA-identical sibling BM and/or PBSC
allogeneic transplants for MM within 18 months of
diagnosis, between 1997 and 2005, reported to the
CIBMTR(Center for International Blood and Marrow
Transplant Research) were identiﬁed. Reduced-intensity
regimens were deﬁned and classiﬁed as non-myeloablative
conditioning (NMA) or RIC based on the standard
deﬁnitions.17 The patients were grouped into those receiv-
ing a single allogeneic HSCT (allo-only) and those receiving
a planned autologous followed by allogeneic HSCT (auto-
allo). Patients who received an autologous HSCT followed
by an unplanned allogeneic HSCT at progression (n¼ 16)
were excluded from the study.
Data source
The CIBMTR is a research organization with more than
450 transplant centers worldwide, which contribute detailed
data on consecutive transplants. Patients are followed
longitudinally, with yearly follow-up. Computerized checks
for errors, physician reviews of submitted data and on-site
audits of participating centers ensure data quality.
Outcomes
OS was deﬁned as the time from date of transplant to date
of death, with survivors censored at the time of last contact.
TRM was deﬁned as death occurring in the absence of
relapse/progressive disease, and summarized by the cumu-
lative incidence estimate with relapse as the competing risk.
Relapse/progression was deﬁned as the time to ﬁrst
evidence of laboratory recurrence or progression of
myeloma according to the standard EBMT/IBMTR
criteria18 and summarized by the cumulative incidence
estimate with TRM as the competing risk. EFS was deﬁned
as survival without progressive disease or relapse from CR.
Progressive disease, relapse from CR and death in
remission were the considered events. Probabilities of
survival and EFS were calculated using the Kaplan–Meier
estimator and compared using the Log-rank test. The
incidence and stage of acute GVHD (aGVHD) were
measured by the standard criteria.19 The incidence of
chronic GVHD (cGVHD) was measured according to the
standard criteria.20
Statistical analysis
Multivariate analyses were performed using Cox propor-
tional hazards models. A stepwise model-building ap-
proach was used to identify the signiﬁcant risk factors
associated with outcomes of TRM, relapse, EFS and OS.
The variables considered in the model-building procedures
were as follows: age at transplant (o50 years vs X50
years), gender (male vs female), Karnofsky performance
score (o90 vs X90 vs unknown), Durie–Salmon stage at
diagnosis (I/II vs III), disease status and sensitivity of MM
to chemotherapy before transplant (sensitive vs not
sensitive vs others), prior lines of chemotherapy (p1
line vs 2 lines vs 42 lines), type of transplant (allo-only
vs auto-allo), donor–recipient sex match (male-to-male vs
male-to-female vs female-to-male vs female-to-female),
conditioning (NMA vs RIC), year of transplant (p2001
vs 42001) and acute and chronic GVHD. At the time of
transplantation, it is unknown who will and who will not
develop GVHD. Therefore, GVHD was treated as a time-
dependent covariate. Because acute and chronic GVHD
effects are the main interests of this study, they were
included in each step of model building. Factors that were
signiﬁcant at a 5% level were kept in the ﬁnal model. The
potential interactions between main effects and all sig-
niﬁcant risk factors were tested. The relative risks of
signiﬁcant covariates based on ﬁnal models were reported.
In addition to considering GVHD as a time-dependent
covariate, we used a landmark analysis method to compute
outcomes stratiﬁed by patients who developed aGVHD
within 100 days. Patients surviving more than 100 days
were included in aGVHD landmark analysis. A similar
landmark study for those who developed cGVHD within 1
year of transplant was also performed. Landmark analysis
results are presented in ﬁgures.
Results
Pre-transplant characteristics
Table 1 summarizes patient, disease and transplant-related
variables of interest. In all, 55% of the patients had IgG
MM and 63% had Salmon–Durie stage III. About 72% of
the patients were in complete or PR at the time of
transplantation and 56% received NMA regimens. The
most common immunosuppressive protocols were CY
combined with mycophenolate mofetil, or CY combined
with MTX.
Outcomes
Table 2 summarizes the univariate outcomes after allo-
geneic HSCT. Table 3 summarizes the results of the
multivariate analysis.
Graft-vs-host disease
The cumulative incidence of aGVHD grades I–IV at 100
days was 42% (95% conﬁdence interval (CI), 35–49%).
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Overall aGVHD grades II–IV was observed in 53 patients
(30%; Table 2).
cGVHD at 1 year was 45% (95% CI, 37–52%). At 5
years, it was 59% (95% CI, 49–69%) with 70% of extensive
cGVHD.
Transplant-related mortality
At 1 year, TRM was 15% (95% CI, 10–20%), and at
5 years it was 25% (95% CI, 17–34%). In multivariate
analysis, aGVHD was associated with an increased risk of
TRM (Table 3, relative risk (RR)¼ 2.42, P¼ 0.016).
cGVHD, whether limited or extensive, had no signiﬁcant
impact on TRM. Figures 1a and b represent the landmark
analyses for TRM in those developing aGVHD within 100
days vs those who did not, and those developing cGVHD
within 1 year vs those who did not.
Relapse
Cumulative incidence of relapse at 1 year was 22% (95%
CI, 16–28%). At 5 years, the incidence of relapse was 52%
(95% CI, 41–63%). aGVHD had no statistically signiﬁcant
effect on the risk of relapse. cGVHD overall was associated
with a reduced risk of relapse in the multivariate analysis,
but the beneﬁcial effect was conﬁned to those with limited
cGVHD (RR¼ 0.35, P¼ 0.035) and was not statistically
Table 2 Univariate outcomes of GVHD, TRM, EFS and OS after
allogeneic HSCT
Outcomes N Eval P (95% CI)
Maximum overall aGVHD grade, N (%) 177
0 92 (52)
I 32 (18)
II 27 (15)
III 23 (13)
IV 3 (2)
aGVHD (grade I–IV) at 100 days 177 42 (35–49)
cGVHD 176
At 1 year 45 (37–52)
At 5 years 59 (49–69)
Extensive cGVHD 59 (70%)
Any GVHD at 5 years 177 72 (65–79)
100-day mortality 177 8 (5–13)
TRM 177
At 1 year 15 (10–20)
At 5 years 25 (17–34)
Relapse/progression 177
At 1 year 22 (16–28)
At 5 years 52 (41–63)
EFS 177
At 1 year 64 (57–71)
At 5 years 22 (13–34)
OS 177
At 1 year 75 (69–82)
At 5 years 38 (26–50)
Abbreviations: aGVHD¼ acute GVHD; cGVHD¼ chronic GVHD;
CI¼ conﬁdence interval; HSCT¼ hematopoietic SCT.
Table 1 Characteristics of patients
Variable N (%)
Patient related
No. of patients 177
No. of centers 65
Age, median (range), years 51 (24–69)
Male sex 102 (58)
Karnofsky score at transplant X90% 121 (68)
Disease related
Immunochemical subtype of MM
IgG 97 (55)
IgA 23 (13)
IgD 4 (2)
Light chain 39 (22)
Non-secretory/other 14 (8)
Salmon–Durie stage at diagnosis
I 8 (4)
II 39 (22)
III 111 (63)
Missing 19 (11)
Albumin at diagnosis o3.5 g/dL 47 (26)
Prior lines of chemotherapy
1 79 (45)
2 43 (24)
X3 25 (14)
Missing/unknown 30 (17)
Disease status before transplant
CR/PR 127 (72)
Minimal response 10 (6)
No. of response/stable disease 16 (9)
Progression 2 (1)
Missing 22 (12)
Bortezomib pre-transplant 8 (5)
Thalidomide pre-transplant 44 (25)
Transplant related
Conditioning regimen
Reduced-intensity conditioning
TBI based 2 (1)
Melphalan p150mg/m2 37 (21)
BU p9mg/kg 13 (7)
Cyclophosphamide 27 (15)
Non-myeloablative conditioning
TBI¼ 200 cGY 54 (31)
Fludarabine+TBI¼ 200 cGY 26 (15)
Other 18 (10)
Donor age, median (range), years 46 (16–73)
Female donor/male recipient 52 (29)
Donor–recipient CMV serostatus, / 43 (24)
PBSC 173 (98)
GVHD prophylaxis
CsA based±MTX 52 (29)
FK506 based±MTX 23 (13)
CSA+MMF 86 (49)
FK506+MMF 2 (1)
Campath±other 2 (1)
Other/unknown 12 (7)
Year of transplant
1997–1999 6 (4)
2000 17 (9)
2001 28 (16)
2002 24 (14)
2003 18 (10)
2004 44 (25)
2005 40 (22)
Median (range) follow-up of survivors, months 29 (3–98)
Abbreviations: FK506¼ tacrolimus; MM¼multiple myeloma; MMF¼myco-
phenolate mofetil.
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signiﬁcant in those with extensive cGVHD (RR¼ 0.58,
P¼ 0.14; Table 3). Figure 2 represents the additional
landmark analysis for relapse in those who developed any
cGVHD within 1 year of HSCT vs those who did not.
The cumulative incidence of relapse at 1 year was 32%
(95% CI, 21–43%) in the allo-only group vs 15% (95% CI,
8–22%) in the auto-allo group. The auto-allo group had a
signiﬁcantly lower risk of relapse in multivariate analysis
compared with the allo-only group (Table 3, RR¼ 0.59,
P¼ 0.043).
Event-free survival
At 1 year, EFS was 64% (95% CI, 57–71%), and at 5 years it
was 22% (95% CI, 13–34%). In the multivariate analysis,
aGVHD and cGVHD overall had no impact on EFS
(Table 3). However, limited cGVHD was associated with
superior EFS (RR for relapse/death¼ 0.40, P¼ 0.027),
whereas extensive cGVHD had no statistically signiﬁcant
impact on EFS. Figure 3 depicts a landmark analysis of EFS
in those developing any cGVHD within 1 year of HSCT vs
those who did not. At 1 year, EFS was 48% (95% CI,
36–60%) in the allo-only group, compared with 74% (95%
CI, 66–83%) in the auto-allo group. At 5 years, EFS was
17% (95% CI, 7–29%) and 24% (95% CI, 7–48%) in the two
groups, respectively. In the multivariate analysis, the auto-allo
group had superior EFS (Table 3, RR¼ 0.57, P¼ 0.008).
Overall survival
At 1 year, survival was 75% (95% CI, 69–82%) and at
5 years it was 38% (95% CI, 26–50%). aGVHD was not
Table 3 Multivariate analysis
Outcome RR (95% CI) P-value
TRMa
aGVHD
No 1.00b
Yes 2.42 (1.18–4.96) 0.016
Relapsec
Type of transplant
First allogeneic 1.00b
Planned autologous+allogeneic 0.59 (0.36–0.98) 0.043
cGVHD
No 1.00b
Limited 0.35 (0.13–0.93) 0.035
Extensive 0.58 (0.29–1.19) 0.14
EFS (RR of relapse/death)d
Type of transplant
First allogeneic 1.00b
Planned autologous+allogeneic 0.57 (0.38–0.86) 0.008
cGVHD
No 1.00b
Limited 0.40 (0.19–0.90) 0.027
Extensive 0.81 (0.47–1.41) 0.56
OS (RR of death)e
aGVHD
First allogeneic
No 1.00b
Yes 0.90 (0.48–1.70) 0.75
Planned autologous+allogeneic
No 1.00b
Yes 3.52 (1.67–7.45) 0.001
Abbreviations: aGVHD¼ acute GVHD; cGVHD¼ chronic GVHD;
CI¼ conﬁdence interval; RR¼ relative risk.
GVHD impact (yes vs no) on outcomes where NS summarized below:
aLimited cGVHD: RR¼ 0.65 (0.17–2.47), P¼ 0.53; extensive cGVHD:
RR¼ 1.50 (0.61–3.70), P¼ 0.37.
bReference group.
caGVHD: RR¼ 0.79 (0.47–1.36), P¼ 0.40.
daGVHD: RR¼ 1.10 (0.72–1.68), P¼ 0.66.
eLimited cGVHD: RR¼ 0.45 (0.18–1.13), P¼ 0.09; extensive cGVHD:
RR¼ 1.18 (0.66–2.10), P¼ 0.59; Test interaction: P(ﬁrst allogeneic¼ planned
autologous+allogeneic)¼ 0.005.
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Figure 1 (a) Acute GVHD and TRM in patients with (grades I–IV) and
without any acute GVHD by day 100 (Landmark analysis). (b) Chronic
GVHD and TRM in patients with and without chronic GVHD within 1
year (Landmark analysis).
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associated with survival in the allo-only cohort (Table 3,
RR of death¼ 0.90, P¼ 0.75). In the auto-allo cohort,
aGVHD was associated with a higher risk of death
(RR¼ 3.52, P¼ 0.001). cGVHD on the other hand, had
no signiﬁcant impact on survival.
Causes of death
The most common cause of death was relapsed or
progressive MM in 33% patients, followed by infections
and organ failure.
Discussion
The aim of this analysis was to deﬁne the impact of GVHD
on outcomes after allogeneic HSCT for MM. aGVHD is
the major underlying cause of morbidity and TRM,
following allogeneic HSCT in patients with MM.6 High
TRM, mainly related to GVHD, made myeloablative
HSCT unacceptable for most patients with MM.8,21
In addition, only a limited number of myeloma patients
are candidates for myeloablative allogeneic HSCT, because
of age, non-availability of HLA-matched donors and
pre-transplant comorbidities. The advent of RIC has led
to an increased number of patients becoming eligible for
HSCT as well as hope of reduced risk of TRM. However,
the success of this modality is dependent on immune-
mediated graft-vs-myeloma effect, because anti-neoplastic
effect derived from the conditioning regimen is modest.
We attempted to evaluate the relative impact of aGVHD
and cGVHD on TRM, relapse and survival endpoints.
In the present study, patients receiving allogeneic HSCT
for MM had a signiﬁcant late risk of relapse (52% at
5 years). A striking ﬁnding is the high number of late
relapses, especially among the patients who did not develop
cGVHD (Figure 2). This is especially striking when we do a
landmark analysis, because relapses occurring during the
ﬁrst year are not included in the ﬁgure. The continuous
increase in relapses is not speciﬁc for this study, but is often
seen in patients undergoing HSCT for myeloma.6,8,10,22
There were signiﬁcant risks of acute and chronic GVHD
consistent with previous observations.22 The probability of
grade III–IV aGVHD after RIC/NMA was 15%. In this
group, mortality from GVHD is typically high.23 Similar to
previous studies in leukemia patients, aGVHD was
associated with a signiﬁcant increase in the risk of TRM
(Table 3), whereas cGVHD overall was not associated with
increased TRM (Table 3, Figure 1b). The negative impact
of aGVHD on survival was marked in the planned auto-
allo cohort.
Several small studies have suggested a graft-vs-MM
effect in patients receiving allogeneic HSCT after myelo-
ablative conditioning.1–5,16 Our study demonstrates that in
the setting of RIC or NMA, cGVHD, especially limited
cGVHD, is associated with beneﬁcial impact with a
decreased risk of myeloma relapse and superior EFS
(Table 3). aGVHD on the other hand had no impact on
relapse. This is in keeping with most studies of the GVL
effect, showing that cGVHD has the strongest association
with decreased relapse, whereas the effect of aGVHD on
relapse was manifested in some, but not in all studies.24–27
A reduced relapse risk was signiﬁcantly associated with
limited, but not extensive cGVHD. This is in contrast to a
study of patients with acute leukemia, showing that there
was no difference in relapse in patients with limited or
extensive cGVHD.25 There may be several reasons why we
did not ﬁnd a reduced relapse risk in patients with extensive
cGVHD. First, this is a multicenter study and there may be
difﬁculties associated with the distinction between limited
and extensive disease. Furthermore, there are a limited
number of patients included and there may not have been
sufﬁcient number of patients to ﬁnd a signiﬁcant effect in
patients with extensive cGVHD. We may also speculate
that patients with extensive cGVHD are treated with more
heavy immunosuppressive therapy that may abrogate the
graft-vs-myeloma effect to a larger extent than the milder
immunosuppression used in patients with limited disease.
In the comparison between allo-only and auto-allo
cohorts, there were signiﬁcantly lower early relapses and
superior EFS in the auto-allo group, compared with the
allo-only group (Table 3). The reason for the reduction in
early relapse and improved EFS in the auto-allo group may
be because of a selection bias favoring more high-risk
patients, proceeding to an initial allogeneic transplant
without a preceding autograft (supplementary data not
shown). The allo-only group had markers of worse
prognosis at baseline, including a higher proportion of
patients with light chain and non-secretory disease
(Po0.001), those with three or more lines of pre-transplant
chemotherapy (P¼ 0.01), and fewer patients with che-
motherapy sensitive disease compared with the auto-allo
group. The allo-only group also received RIC including
melphalan (Po0.001)-based conditioning more often,
suggesting a higher intensity of conditioning within the
reduced-intensity category. This is also consistent with the
notion that some of these patients were selected because
they had more advanced disease and were considered for
more ‘intensive conditioning’ within the RIC spectrum.
There was no increase in TRM associated with cGVHD
(Table 3). This suggests that any graft-vs-MM effect
induced by cGVHD not only decreased the probability of
relapse, but also had no adverse effect on survival. A study
by Crawley et al.16 showed that cGVHD was associated
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with improved EFS. No signiﬁcant impact on EFS by
aGVHD was observed despite of its association with higher
risk of TRM. The reason for this mitigating effect may be
an association between aGVHD and cGVHD (P¼ 0.03).
The increased mortality risk associated with aGVHD was
statistically signiﬁcant in the auto-allo group, but not in the
allo-only group. The reason for this may also be because of
the selection of higher-risk patients in the allo-only group.
cGVHD had no impact on OS despite lower relapse and
unchanged TRM. Also the impact of cGVHD on quality of
life and comorbidities cannot be measured in this analysis.
This also suggests that currently the role of allotransplan-
tation in MM remains limited by lack of adequate long-
term disease control, a persistent risk of relapse and death
from recurrent myeloma. These ﬁndings are consistent with
emerging data from randomized studies such as the
BMTCTN 0102 study.15
In conclusion, our analysis demonstrates a beneﬁcial
effect on relapse risk reduction associated with limited
cGVHD without an increased risk of TRM. These ﬁndings
have implications for clinical practice and future trials in
allogeneic HSCT for MM. In this study, 59% of the
patients with aGVHD developed cGVHD and 30% of
them had limited cGVHD. In clinical practice, this ﬁgure
may be increased by an early discontinuation of immuno-
suppression in the absence of GVHD.28 However, early
immunosuppression should be best available to prevent
aGVHD, because it was associated with an increased risk
of TRM and decreased survival. These ﬁndings could also
prompt wider use of donor lymphocyte infusions to induce
graft-vs-myeloma effect in selected settings. Despite the
promise of a graft-vs-myeloma effect, the major current
shortcoming of allogeneic transplantation in MM is the
ongoing risk of relapse. These are best addressed in
prospective trials incorporating more novel conditioning
and maintenance strategies.
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